Cost Offsets from Recommended Medications for Medicare Beneficiaries with Diabetes AcademyHealth June 9, 2008 Bruce Stuart,* Linda Simoni-Wastila,* Lirong.

Slides:

Advertisements

Similar presentations

Disease Burden and Intensity of Antidiabetic Drug Use by Medicare Beneficiaries with Diabetes: Will Part D Make a Difference? AcademyHealth June 25, 2006.

Advertisements

Evaluation of National Drug Use Reviews to Improve Patient Safety in Nursing Homes Becky Briesacher, PhD 1 Rhona Limcangco, MPharm 2 Linda Simoni-Wastila,

Understanding Changes in Local Public Health Spending Glen Mays, PhD, MPH Department of Health Policy and Management University of Arkansas for Medical.

Estimating the moral hazard effect of prescription drug coverage AcademyHealth Annual Meeting Boston, MA June 28, 2005 Department of Health Policy and.

Reduction of Medicaid Expenditures from State Prescription Programs in Illinois and Wisconsin Donald S Shepard, PhD* Desiree Koh, * Cindy Thomas, PhD*

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.

Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.

Journal Club Alcohol and Health: Current Evidence March-April 2006.

RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.

Variation in Antipsychotic Medication Use and Expenditures Across State Medicaid Programs Jacqueline R. Chaudhry.

The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older Dana P. Goldman, Federico Girosi et al. American Journal of Public Health November.

The Association between Antenatal Depression and Adverse Birth Outcomes among Women Receiving Medicaid in Washington State Amelia R. Gavin, PhD School.

Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care Trends in the.

Gaps in Supplemental Health Insurance for Disabled Medicare Beneficiaries Jill Klingner MS RN Rural Health Research Center University of Minnesota AcademyHealth.

THE PREVALENCE AND PREDICTORS OF LOW-COST GENERIC PROGRAM USE IN A NATIONALLY REPRESENTATIVE ADULT POPULATION: IMPLICATIONS FOR PATIENTS, RESEARCH, AND.

Impact of Multi-Tiered Copayments on Cost and Use of Prescription Drugs among the Elderly Presented at AcademyHealth Annual Research Meeting Presented.

DataBrief: Did you know… DataBrief Series ● January 2012 ● No. 26 Dual Eligibles, Chronic Conditions, and Functional Impairment By Age Group In 2009, 29%

Clinical Impact of Adherence to Pharmacotherapeutic Guidelines on the Outcome in Patients with Chronic Heart Failure Suntheep Batra, M.Pharm Department.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care Provision of Preventive Services in the Complex Patient AHRQ.

The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.

TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.

The Impact of National Health Reform on Adults with Mental Disorders Rachel L. Garfield, Ph.D. Department of Health Policy & Management, University of.

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential.

Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz workers) in Iran: a nationally representative observational.

Value-Based Insurance Design A “Clinically Sensitive” Approach to Preserve Quality of Care and Contain Cost.

Presented by Dr. Soe Sandi Tint

Racial Differences in the Impact of HMO Coverage of Diabetes Blood Glucose Monitors on Self-Monitoring Connie A. Mah, M.S. Department of Ambulatory Care.

Disparities in the Adequacy of Depression Treatment in the United States Jeffrey S. Harman, Ph.D. University of Florida Mark J. Edlund, M.D., Ph.D. John.

The Impact of Health Expenses on Older Women ’ s Financial Security Juliette Cubanski, Ph.D. The Henry J. Kaiser Family Foundation AcademyHealth 2007 Annual.

INTENSITY OF HEALTH SERVICES AND COSTS OF CARE FOR PREVIOUSLY UNINSURED MEDICARE BENEFICIARIES J. Michael McWilliams, M.D. Division of General Medicine.

Gaps in Drug Benefits: Impact on Utilization and Spending for Drugs Used by Medicare Beneficiaries with Serious Mental Illness Linda Simoni-Wastila, PhD.

Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.

Assessing the Distributional Impact of Social Programs The World Bank Public Expenditure Analysis and Manage Core Course Presented by: Dominique van de.

DataBrief: Did you know… DataBrief Series ● October 2011 ● No. 24 Medicare’s Highest Spenders In 2006, Medicare spent almost 90 times more per capita on.

DataBrief: Did you know… DataBrief Series ● October 2011 ● No. 20 Seniors with Chronic Conditions and Functional Impairment In 2006, over 26% of seniors.

Exploring The Determinants Of Racial & Ethnic Disparities In Total Knee Arthroplasty: Health Insurance, Income And Assets Amresh Hanchate, PhD Health Care.

Chart 1.1: Total National Health Expenditures, 1980 – 2011 (1) Source: Centers for Medicare & Medicaid Services, Office of the Actuary. Data released.

National Commission for Quality Long Term Care Testimony of George Taler, MD Director, Long Term Care Washington Hospital Center Washington, DC Past President,

How Much Would A Medicare Prescription Drug Benefit Cost? Offsets in Medicare Part A Cost by Increased Drug Use Zhou Yang, Ph.D. Assistant Professor Department.

Managed Care, Drug Benefits and Mortality: An Analysis of the Elderly Gautam Gowrisankaran Washington University / NBER Robert.

Medicare Savings Due to Prescription Drug Coverage for Near-poor Elders Christine Bishop, Ph.D. 1 Andrew Ryan, M.A. 1 Daniel Gilden, M.S. 2 Cindy Parks.

Medicare Home Health and The Role of Physicians Jennifer L. Wolff, Ann Meadow, Carlos O. Weiss, Cynthia M. Boyd, Bruce Leff June 2008.

Quantifying uncertainty in long-term care costs following introduction of new drug therapy: the importance of model choice Paul McNamee, Alessandra Vanoli,

Employer-Sponsored Health Insurance for Early Retirees: Impacts on Retirement, Health and Health Care Erin Strumpf, Ph.D. McGill University AcademyHealth.

Individual Insurance Benefits to be Available under Health Reform Would Have Cut Out-Of-Pocket Spending in Steven C. Hill Center for Financing,

How Big a Problem is Obesity for the Medicare Program? AcademyHealth June 10, 2008 Bruce Stuart, Lirong Zhao, Jennifer Lloyd The Peter Lamy Center Drug.

Drug Coverage, Disease Burden, and the Intensity of Medication Use among Medicare Beneficiaries Seattle, Washington AcademyHealth June 27, 2006 Bruce Stuart,

THE URBAN INSTITUTE Examining Long-Term Care Episodes and Care History for Medicare Beneficiaries: A Longitudinal Analysis of Elderly Individuals with.

Obesity, Medication Use and Expenditures among Nonelderly Adults with Asthma Eric M. Sarpong AHRQ Conference September 10, 2012.

The Effects of Health Plan Performance Measurement on Quality of Care for Medicare Beneficiaries Presented by Kate Bundorf Co-authors: Laurence Baker and.

Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.

Prescription Drugs, Medical Care, and Health Outcomes: A Model of Elderly Health Dynamics Zhou Yang, Emory University Donna B. Gilleskie, Univ of North.

1 Cost Sharing for Low-Income Beneficiaries and Supplementing Part D Examples from Pharmacy Plus Medicaid Demonstration Programs Summit for State Health.

DataBrief: Did you know… DataBrief Series ● October 2011 ● No. 21 Dual Eligibles, Chronic Conditions, and Functional Impairment In 2006, 37% of seniors.

Rx Coverage, Use and Spending Among US Seniors: Where Did Things Stand on the Eve of Part D Implemention & How Can This Inform Us Now? Presented at: AcademyHealth.

Improving Value in Health Care: Challenges and Potential Strategies Arnold M Epstein October 24, 2008 Congressional Health Care Reform Education Project.

Oregon's Coordinated Care Organizations: First Year Expenditure and Utilization Authors: Neal Wallace, PhD, Peter Geissert, MPH 1, and K. John McConnell,

Presented at The 129th Annual Meeting of the American Public Health Association Atlanta, GA, October 21–25, 2001 Presented by Amanda A. Honeycutt Linda.

Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Prescription Drug Coverage Enrollment in Beneficiaries With Glaucoma Blumberg.

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential.

Prescription Drug Demand for Therapeutic Substitutes: Do Copayments and Insurer Non- Price Rationing Influence Patient Utilization? Dominick Esposito AcademyHealth.

Impact of Prescription Drug Coverage on Medicare Program Expenditures: Will Part D Produce Savings in Part A and Part B? Bruce Stuart, PhD* Becky Briesacher,

Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,

Date:2017/10/03 Presenter: Wen-Ching Lan

Visual Impairment Monetary Dependency Ratios over Time

BURDEN OF ILLNESS IN CYSTIC FIBROSIS: A RETROSPECTIVE ANALYSIS OF MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA Pratyusha Vadagam, MS Candidate,1 Khalid.

Cost Sharing Under Part D: Impact on Beneficiaries with the Standard Benefit Bruce Stuart, PhD Director, Peter Lamy Center on Drug Therapy and Aging.

Jessica Banthin, Ph.D December 11, 2007

Presentation transcript:

Cost Offsets from Recommended Medications for Medicare Beneficiaries with Diabetes AcademyHealth June 9, 2008 Bruce Stuart,* Linda Simoni-Wastila,* Lirong Zhao,* Jennifer Lloyd,* Jalpa Doshi** *The Peter Lamy Center on Drug Therapy and Aging, University of Maryland Baltimore **University of Pennsylvania School of Medicine

Page 2 The Peter Lamy Center on Drug Therapy and Aging Background Burden of Diabetes on the Medicare Program 25% of Medicare beneficiaries have diabetes mellitus (DM) Beneficiaries with DM spend 50% more on medical care Can drug regimens for DM reduce costs in traditional Medicare? Clinical trial studies Observational studies Decision analysis (Rosen et al., 2005)

Page 3 The Peter Lamy Center on Drug Therapy and Aging Study Objectives 1.Assess impact of utilization and spending for selected classes of drugs recommended by DM guidelines on spending for traditional Medicare services. Antidiabetic agents (older and newer oral hypoglycemic agents, insulin) RAASIs (ACE inhibitors, ARBs) Statins and other lipid lowering medications 2.Determine whether impacts vary with beneficiaries’ overall burden of illness

Page 4 The Peter Lamy Center on Drug Therapy and Aging Data and Study Sample Data Pooled panel of MCBS files, Study Sample Inclusion criteria: self report of DM and/or ICD-9 codes: 250.xx, 357.2, , , Exclusion criteria: LTC resident, enrolled in Medicare less than full year, Medicare HMO enrollee, incomplete surveys Final study sample: N=7,441 individuals contributing 14,317 person-year observations

Page 5 The Peter Lamy Center on Drug Therapy and Aging Measures Burden of Illness Sample divided into quintiles based on cumulative medical spending Dependent Variable Annual Medicare payments in constant 2006 dollars Explanatory Variables Drug utilization/spending, demographics (age, sex, race, census region), economic variables (income, prescription coverage), health (self-reported, ADLs, BMI, diabetes complications, chronic kidney disease, hypertension, CAD, CHF, hyperlipidemia, COPD, arthritis, death), denominator days

Page 6 The Peter Lamy Center on Drug Therapy and Aging Analytical Strategy Quintile-specific Medicare expenditure regressions with person-year as unit of analysis - drug user versus nonuser - fills per user of each drug type - Spending on each drug type All models estimated using GLM with gamma distribution and log link in Stata with robust command to control for repeated measures Extensive sensitivity tests including difference equations

Page 7 The Peter Lamy Center on Drug Therapy and Aging Selected Descriptive Results

Page 8 The Peter Lamy Center on Drug Therapy and Aging Annual Medicare Spending by Quintile for Study Sample with Diabetes (2006 $)

Page 9 The Peter Lamy Center on Drug Therapy and Aging Annual Spending on Antidiabetic Drugs (2006 $)

Page 10 The Peter Lamy Center on Drug Therapy and Aging Annual Spending on RAASIs and Lipid Lowering Drugs (2006 $)

Page 11 The Peter Lamy Center on Drug Therapy and Aging Selected Multivariate Results

Page 12 The Peter Lamy Center on Drug Therapy and Aging Marginal Effects on Medicare Spending of Being a Medication User Drug ClassFull SampleQuintile 1Quintile 5 Older DM Drugs-$577**-$8-$2,313* Newer AD drugs-$268$47-$1,620 Insulins$1,242-$98*$1,807 ACE inhibitors-$674**-$100**-$1,727 ARBs-$709**-$37-$670 Statins-$380-$79**-$362 Other LL drugs$318-$88*-$336 * p<.05; ** p<.01

Page 13 The Peter Lamy Center on Drug Therapy and Aging Marginal Effects on Medicare Spending of an Additional Prescription Fill by Medication Users Drug ClassFull SampleQuintile 1Quintile 5 Older AD drugs-$71.12**-$7.59**-$406.87** Newer AD drugs$66.29$4.66-$ ACE inhibitors-$164.24**-$8.95*-$331.83* ARBs-$158.53*-$5.51-$ Statins-$107.01*-$15.09**-$460.80* *p<,05; **p<.01 Note: Insulin and other LL drugs dropped due to small samples

Page 14 The Peter Lamy Center on Drug Therapy and Aging Marginal Effects on Medicare Spending of an Additional $ in Drug Spending Drug ClassFull SampleQuintile 1Quintile 5 Older DM Drugs-$1.65**-$0.11**-$9.32** Newer AD drugs-$0.10-$0.11-$1.47 Insulins$2.41-$0.23$6.86 ACE inhibitors-$2.52**-$0.34**-$5.76* ARBs-$2.52**-$0.12-$6.77* Statins-$0.59**-$0.22**-$3.20** Other LL drugs-$0.76-$0.39**-$8.54** * p<.05; ** p<.01

Page 15 The Peter Lamy Center on Drug Therapy and Aging Conclusions Being a medication user matters. - Users of older ADs, ACEIs, and ARBs spent between $577 and $709 less on Medicare services compared to nonusers, ceteris paribus Persistency in use matters. - Each added prescription fill by users of the 3 drug groups is associated with between $71 and $164 in lower Medicare costs

Page 16 The Peter Lamy Center on Drug Therapy and Aging Conclusions Drug prices matter. - Older AD drugs (primarily generics) cost $49 per fill compared to $163 per fill for newer AD agents (2006 $) Overall burden of illness matters most. - For example each dollar spent on older AD drugs by beneficiaries in quintile 1 is associated with 11 cents in lower Medicare costs, but that same dollar is associated with $9.32 less for those in quintile 5

Page 17 The Peter Lamy Center on Drug Therapy and Aging Limitations MCBS drug data are self-reported—possible under-reporting Newer oral AD drugs may be under-represented Possibility of unobserved confounders Data are prior to implementation of Medicare Part D - 70% of sample had drug coverage compared to 90% today

Page 18 The Peter Lamy Center on Drug Therapy and Aging Implications for Medicare Part D Improving prevalence and persistency of use of medications recommended for older individuals with diabetes is potentially cost saving to Medicare Highest potential returns from targeting interventions to high spenders (medication therapy management) Greatest long-term returns may lie at the other end of the spectrum if improved medication regimens reduce future complications of diabetes

Thank You!